[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Liu et al., 2021 - Google Patents

APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia

Liu et al., 2021

View HTML
Document ID
13251608424599710394
Author
Liu C
Murray M
Li X
Zhao N
Wang N
Heckman M
Shue F
Martens Y
Li Y
Raulin A
Rosenberg C
Doss S
Zhao J
Wren M
Jia L
Ren Y
Ikezu T
Lu W
Fu Y
Caulfield T
Trottier Z
Knight J
Chen Y
Linares C
Wang X
Kurti A
Asmann Y
Wszolek Z
Smith G
Vemuri P
Kantarci K
Knopman D
Lowe V
Jack Jr C
Parisi J
Ferman T
Boeve B
Graff-Radford N
Petersen R
Younkin S
Fryer J
Wang H
Han X
Frieden C
Dickson D
Ross O
Bu G
Publication year
Publication venue
Science translational medicine

External Links

Snippet

Apolipoprotein E (APOE) genetic variants have been shown to modify Alzheimer's disease (AD) risk. We previously identified an APOE3 variant (APOE 3-V236E), named APOE3- Jacksonville (APOE3-Jac), associated with healthy brain aging and reduced risk for AD and …
Continue reading at www.science.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Similar Documents

Publication Publication Date Title
Liu et al. APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia
Kovacs Astroglia and tau: new perspectives
Davis et al. APOE genotype regulates pathology and disease progression in synucleinopathy
De Roeck et al. The role of ABCA7 in Alzheimer’s disease: evidence from genomics, transcriptomics and methylomics
Koutsodendris et al. Apolipoprotein E and Alzheimer's disease: findings, hypotheses, and potential mechanisms
Deming et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk
Young-Pearse et al. Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer’s disease
Huang Apolipoprotein E and Alzheimer disease
Shao et al. Genetics of Alzheimer’s disease: From pathogenesis to clinical usage
Penzes et al. Dendritic spine pathology in neuropsychiatric disorders
Castellano et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance
Saunders Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses
Ringman et al. Genetic heterogeneity in Alzheimer disease and implications for treatment strategies
Zandi et al. Amygdala and anterior cingulate transcriptomes from individuals with bipolar disorder reveal downregulated neuroimmune and synaptic pathways
Zhu et al. State of play in Alzheimer’s disease genetics
Van Herpen et al. Variable phenotypic expression and extensive tau pathology in two families with the novel tau mutation L315R
Yasuda et al. A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration
Calero et al. Additional mechanisms conferring genetic susceptibility to Alzheimer’s disease
van der Zee et al. Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD
Stopschinski et al. Anatomic survey of seeding in Alzheimer’s disease brains reveals unexpected patterns
Narasimhan et al. Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway
Yan et al. FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease
Brickell et al. Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer’s disease
Latimer et al. Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease
Huang et al. The impact of increasing levels of blood C-reactive protein on the inflammatory loci SPI1 and CD33 in Alzheimer’s disease